Centene (CNC) Earnings Date & Reports

Key Takeaways

• Centene reported third-quarter 2026 adjusted diluted earnings per share (EPS) of $0.58, up 16% from $0.50 a year earlier and well ahead of Wall Street estimates.
• Total revenue reached $50.65 billion, rising 1.9% year over year and beating consensus forecasts by a wide margin.
• The company raised its full-year 2026 adjusted EPS guidance to more than $5.20 per share, up from a prior floor of $4.80.
• Medicare Advantage is now on track to reach breakeven in 2026, a full year ahead of management's original turnaround timeline.
• The consolidated health benefits ratio (HBR), which measures the share of premiums spent on medical claims, held steady at 92.7% and came in better than expected.
• Total membership declined to 25.7 million as Centene continued to manage through Medicaid eligibility changes and marketplace attrition.
• For more detail on this ticker's developments, explore its Major News, Today's Price Move, Price Targets, and Forecast on dedicated pages.
• To discover automated strategies and market ideas, explore Trending AI Robots.

Earnings Context and Why It Matters

Centene Corporation (NYSE: CNC), a leading U.S. managed care organization focused on government-sponsored health programs, delivered third-quarter 2026 results that underscore a meaningful inflection in its multiyear margin-recovery story. The report matters because Centene has spent recent quarters repairing profitability across its Medicaid, Medicare, and marketplace businesses while absorbing the effects of lower enrollment and the prior year's large goodwill impairment. A beat on earnings and revenue, combined with a raised full-year outlook and an earlier-than-expected Medicare Advantage breakeven, signals that management's cost and pricing discipline is translating into results. For investors, the update provides a clearer view into how Centene plans to balance shrinking membership with improving underwriting margins heading into 2027.

Reported Results

Centene reported adjusted diluted EPS of $0.58 for the quarter ended September 30, 2026, up 16% from $0.50 a year ago and sharply above the consensus estimate of around $0.07. Total revenue came in at $50.65 billion, a 1.9% year-over-year increase that exceeded expectations. On a GAAP (Generally Accepted Accounting Principles) basis, the company posted a diluted loss per share of $0.14, reflecting severance and other optimization-related charges, while adjusted net earnings rose 18.4% to $290 million.

Premium and service revenue totaled $45.1 billion, up 0.5%, driven by Prescription Drug Plan (PDP) membership growth and Medicaid rate increases. The consolidated health benefits ratio held at 92.7%, better than expected and a 30-basis-point sequential improvement. Segment performance varied: Medicare revenue jumped 19.9% to $11.3 billion, Medicaid revenue rose 4% to $24.1 billion, and commercial revenue fell 21% to $8.7 billion amid marketplace attrition.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking earnings movers like Centene, the AI Screener offers a structured way to surface actionable candidates across the broader healthcare and managed care landscape.

Market Reaction and Investor Sentiment

Investors responded favorably to the results, with Centene shares trading higher following the release and approaching a 52-week high. The positive reaction reflected the magnitude of the earnings beat, the upward revision to full-year guidance, and confirmation that the Medicare Advantage turnaround is progressing faster than planned. Sentiment was further supported by disciplined debt reduction, which lowered the company's total debt and interest expense. At the same time, attention remains focused on enrollment trends, as continued declines in Medicaid and marketplace membership are expected to persist into 2027, tempering some of the optimism around margin gains.

Forward Outlook and Key Factors to Monitor

Centene enters the fourth quarter with raised expectations. Management now projects full-year 2026 adjusted EPS above $5.20 and total revenue between $196.5 billion and $200.5 billion, with a full-year HBR target of roughly 90.4% to 91.1%. The company expects the Medicare Advantage segment to reach breakeven in 2026, a year ahead of schedule, and marketplace pretax margin is now seen at the top of its prior range.

Looking ahead, investors should watch several key factors. First, Medicaid membership is expected to decline 8% to 9% by year-end, and further attrition is anticipated in 2027 as states implement work requirements and eligibility terminations under the One Big Beautiful Bill Act (OB3). Roughly 40% of Medicaid revenue is scheduled to re-rate at the start of 2027, making state rate decisions a critical swing factor for margin stability.

Second, management has signaled that Medicare Advantage membership will likely be down year over year in 2027 as the company prioritizes margin expansion over growth, while PDP margins are expected to reset lower from their strong 2026 levels. Finally, cost trends in areas such as behavioral health, home health, and high-cost drugs, along with regulatory and program-integrity adjustments, will remain central to whether Centene can sustain its improved profitability into 2027.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations